UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000043774 |
|---|---|
| Receipt number | R000049809 |
| Scientific Title | Ranger drug-coated balloon catheters post market surveillance |
| Date of disclosure of the study information | 2021/06/01 |
| Last modified on | 2025/04/07 11:33:38 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Ranger drug-coated balloon catheters post market surveillance
Acronym
Ranger drug-coated balloon catheters post market surveillance
Scientific Title
Ranger drug-coated balloon catheters post market surveillance
Scientific Title:Acronym
Ranger drug-coated balloon catheters post market surveillance
Region
| Japan |
Condition
Condition
Superficial femoral and proximal popliteal artery disease
Classification by specialty
| Cardiology | Surgery in general | Vascular surgery |
| Radiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The purpose of this surveillance is to understand the situation of occurrence of failure in order to ensure the safety of the product, as well as to collect data on the safety and efficacy of this product in clinical practice.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Others
Trial characteristics_2
Others
Developmental phase
Not applicable
Assessment
Primary outcomes
- Implementation rate of target lesion revascularization (TLR)
- Occurrence rate of AE and device malfunction
- Mortality rate
Key secondary outcomes
- Death of any cause and target limb amputation during the follow-up (procedure, pre-discharge, 1, 6, 12 and 24 months) period
- SAE for which relation to the Ranger DCB or procedures cannot be denied during the follow-up period
- Device malfunction and adverse event for which the relation to Ranger DCB or procedures cannot be denied during the follow-up period
- Duration of Ranger DCB related DAPT at pre-procedure and during the follow-up period
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients intended to be treated with Ranger DCB catheter
Key exclusion criteria
Not applicable
Target sample size
200
Research contact person
Name of lead principal investigator
| 1st name | Kazuo |
| Middle name | |
| Last name | Kawahara |
Organization
Boston Scientific Japan K.K.
Division name
Clinical Sciences
Zip code
164-0001
Address
4-10-2 Nakano, Nakano-ku, Tokyo, 164-0001 Japan
TEL
03-6853-7500
JapanClinicalTrials@bsci.com
Public contact
Name of contact person
| 1st name | Yuji |
| Middle name | |
| Last name | Kato |
Organization
Boston Scientific Japan K.K.
Division name
Clinical Sciences
Zip code
164-0001
Address
4-10-2 Nakano, Nakano-ku, Tokyo, 164-0001 Japan
TEL
03-6853-7500
Homepage URL
JapanClinicalTrials@bsci.com
Sponsor or person
Institute
Boston Scientific Japan K.K.
Institute
Department
Personal name
Funding Source
Organization
Boston Scientific Japan K.K.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Not applicable
Address
Not applicable
Tel
Not applicable
Not applicable
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 06 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2021 | Year | 03 | Month | 16 | Day |
Date of IRB
| 2021 | Year | 06 | Month | 29 | Day |
Anticipated trial start date
| 2021 | Year | 08 | Month | 13 | Day |
Last follow-up date
| 2024 | Year | 12 | Month | 27 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Not applicable
Management information
Registered date
| 2021 | Year | 03 | Month | 29 | Day |
Last modified on
| 2025 | Year | 04 | Month | 07 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049809
